229 related articles for article (PubMed ID: 28185693)
21. Quick reference guide to apixaban.
Hurst KV; O'Callaghan JM; Handa A
Vasc Health Risk Manag; 2017; 13():263-267. PubMed ID: 28744136
[TBL] [Abstract][Full Text] [Related]
22. Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions.
Pan EY; Sobieraj DM
Conn Med; 2016 Feb; 80(2):105-11. PubMed ID: 27024982
[No Abstract] [Full Text] [Related]
23. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Piccini JP; Lopes RD; Mahaffey KW
Curr Opin Cardiol; 2010 Jul; 25(4):312-20. PubMed ID: 20520539
[TBL] [Abstract][Full Text] [Related]
24. Role of orally available antagonists of factor Xa in the treatment and prevention of thromboembolic disease: focus on rivaroxaban.
Morell J; Sullivan B; Khalabuda M; McBride BF
J Clin Pharmacol; 2010 Sep; 50(9):986-1000. PubMed ID: 20124518
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness and safety of oral direct factor Xa inhibitors for the treatment of venous thromboembolism in patients with cancer and/or older age.
Sato D; Ikeda S; Koga S; Yamagata Y; Eguchi M; Yonekura T; Tsuneto A; Yoshimuta T; Koide Y; Kawano H; Maemura K
Heart Vessels; 2019 Apr; 34(4):678-687. PubMed ID: 30341629
[TBL] [Abstract][Full Text] [Related]
26. Using new oral anticoagulants in patients undergoing major orthopedic surgery.
Bass AR
Curr Rheumatol Rep; 2015 Apr; 17(4):25. PubMed ID: 25854486
[TBL] [Abstract][Full Text] [Related]
27. Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan.
Nakamura M; Yamada N; Ito M
J Atheroscler Thromb; 2017 Jun; 24(6):560-565. PubMed ID: 28392512
[TBL] [Abstract][Full Text] [Related]
28. Role of agents for reversing the effects of target-specific oral anticoagulants.
Riley TR; Gauthier-Lewis ML; Sanchez CK; Douglas JS
Am J Health Syst Pharm; 2017 Jan; 74(2):54-61. PubMed ID: 27895055
[TBL] [Abstract][Full Text] [Related]
29. Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series.
Beyer-Westendorf J; Michalski F; Tittl L; Hauswald-Dörschel S; Marten S
Lancet Haematol; 2016 Oct; 3(10):e480-e488. PubMed ID: 27692306
[TBL] [Abstract][Full Text] [Related]
30. Risk impact of edoxaban in the management of stroke and venous thromboembolism.
Hurst KV; O'Callaghan JM; Handa A
Vasc Health Risk Manag; 2016; 12():329-35. PubMed ID: 27563246
[TBL] [Abstract][Full Text] [Related]
31. Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban.
Apostolakis S; Lip GY
Expert Opin Investig Drugs; 2012 Jul; 21(7):1057-64. PubMed ID: 22616561
[TBL] [Abstract][Full Text] [Related]
32. Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.
Kubli KA; Snead JA; Cheng-Lai A
Cardiol Rev; 2016; 24(4):205-10. PubMed ID: 26991962
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism.
Kimpton M; Carrier M
Expert Opin Drug Saf; 2019 Apr; 18(4):313-320. PubMed ID: 30925842
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamics, pharmacokinetics and clinical efficacy of apixaban in the treatment of thrombosis.
Zheng SS; Chong JJ; Chong BH
Expert Opin Drug Metab Toxicol; 2016 May; 12(5):575-80. PubMed ID: 26982962
[TBL] [Abstract][Full Text] [Related]
35. Direct oral anticoagulants: evidence and unresolved issues.
Chan N; Sobieraj-Teague M; Eikelboom JW
Lancet; 2020 Nov; 396(10264):1767-1776. PubMed ID: 33248499
[TBL] [Abstract][Full Text] [Related]
36. Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model.
Lester PA; Coleman DM; Diaz JA; Jackson TO; Hawley AE; Mathues AR; Grant BT; Knabb RM; Ramacciotti E; Frost CE; Song Y; Wakefield TW; Myers DD
Arterioscler Thromb Vasc Biol; 2017 May; 37(5):942-948. PubMed ID: 28232327
[TBL] [Abstract][Full Text] [Related]
37. [What role for the direct oral anticoagulants in oncology?].
Lebellec L; Kouakam C; Bertrand N; Penel N
Bull Cancer; 2018; 105(7-8):631-633. PubMed ID: 29960639
[No Abstract] [Full Text] [Related]
38. Reversal of Factor Xa Inhibitors by Andexanet Alfa May Increase Thrombogenesis Compared to Pretreatment Values.
Siddiqui F; Tafur A; Ramacciotti LS; Jeske W; Hoppensteadt D; Ramacciotti E; Iqbal O; Fareed J
Clin Appl Thromb Hemost; 2019; 25():1076029619863493. PubMed ID: 31298056
[TBL] [Abstract][Full Text] [Related]
39. New oral anticoagulants for the treatment of venous thromboembolism.
Agnelli G; Becattini C; Franco L
Best Pract Res Clin Haematol; 2013 Jun; 26(2):151-61. PubMed ID: 23953903
[TBL] [Abstract][Full Text] [Related]
40. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
Sardar P; Chatterjee S; Lavie CJ; Giri JS; Ghosh J; Mukherjee D; Lip GY
Int J Cardiol; 2015 Jan; 179():279-87. PubMed ID: 25464465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]